{"id":"W4307970770","doi":"10.1158/1078-0432.ccr-21-3577","title":"Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and <i>BRCA1, BRCA2</i> , or <i>ATM</i> Alterations Identified by Testing Circulating Tumor DNA","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; Juravinski Cancer Centre; Institute of Cancer Research","funders":"Medical Research Council; National Institute for Health and Care Research; AstraZeneca","keywords":"Olaparib; Medicine; Enzalutamide; Hazard ratio; Internal medicine; Oncology; Cohort; Prostate cancer; Population; Cancer; Confidence interval; Progression-free survival; PARP inhibitor; Chemotherapy; Poly ADP ribose polymerase; Biology; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002582453,0.0002622158,0.0006076526,0.0002683679,0.0009190499,0.0001883261,0.0002237146,0.00004814998,0.0004485991],"category_scores_gemma":[0.001067632,0.0001915519,0.00006611072,0.001736364,0.0005001222,0.0002303391,0.0003023609,0.001503534,0.000006242733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000805454,"about_ca_system_score_gemma":0.00251243,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002438561,"about_ca_topic_score_gemma":0.001205657,"domain_scores_codex":[0.9947241,0.0007424944,0.0009573887,0.0009438175,0.00168973,0.0009424589],"domain_scores_gemma":[0.9964579,0.001789897,0.0002009407,0.0004234128,0.0006950545,0.0004328195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01447285,0.003384618,0.9432483,0.0005882742,0.0004302239,0.0006803665,0.001369662,0.0003492169,0.006172261,0.00002871069,0.006795404,0.02248014],"study_design_scores_gemma":[0.05532954,0.008501424,0.9224954,0.00125769,0.0003251297,0.00003401272,0.001457503,0.001644147,0.001493988,0.0001163396,0.006531442,0.0008134172],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921794,0.0017389,0.000002017768,0.002179123,0.0001397985,0.002971882,0.0005433431,0.00004354206,0.0002019965],"genre_scores_gemma":[0.9943897,0.0002282073,0.0002128273,0.00037669,0.0001145048,0.002224623,0.0002666997,0.00006832369,0.002118415],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04085669,"threshold_uncertainty_score":0.7811261,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1885218549173735,"score_gpt":0.46875579997178,"score_spread":0.2802339450544065,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}